All In Biotech

Drug Trial Radar · NCT05484349

TIzanidine for the Preventive Treatment of Episodic MigrainE (TIME)

Safety and Efficacy of Oral Tizanidine Hydrochloride in Preventing Migraine Attacks in Adult Migraine Patients: a Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study

Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

189

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Dec 25, 2025

Study completion Dec 25, 2025

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Sichuan Credit Pharmaceutical Co., Ltd.
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study,189 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Tizanidine Hydrochloride in preventing migraine attacks in episodic migraine in adults.

Conditions

  • Migraine Without Aura
  • Migraine With Aura

Interventions

  • Tizanidine HydrochlorideDrug

    Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks

  • Tizanidine HydrochlorideDrug

    Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks

  • Tizanidine Hydrochloride PlaceboDrug

    Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change of Migraine Days.Time frame: 12-week treatment period(Day 1-Day 84)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The First Hospital of Jiaxing

    Jiaxing, Zhejiang, China · Recruiting

  • Affiliated Hospital of Shaoxing University

    Shaoxing, Zhejiang, China · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.